51
|
Cheng SL, Ramachandran B, Behrmann A, Shao JS, Mead M, Smith C, Krchma K, Bello Arredondo Y, Kovacs A, Kapoor K, Brill LM, Perera R, Williams BO, Towler DA. Vascular smooth muscle LRP6 limits arteriosclerotic calcification in diabetic LDLR-/- mice by restraining noncanonical Wnt signals. Circ Res 2015; 117:142-56. [PMID: 26034040 DOI: 10.1161/circresaha.117.306712] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2015] [Accepted: 05/28/2015] [Indexed: 11/16/2022]
Abstract
RATIONALE Wnt signaling regulates key aspects of diabetic vascular disease. OBJECTIVE We generated SM22-Cre;LRP6(fl/fl);LDLR(-/-) mice to determine contributions of Wnt coreceptor low-density lipoprotein receptor-related protein 6 (LRP6) in the vascular smooth muscle lineage of male low-density lipoprotein receptor-null mice, a background susceptible to diet (high-fat diet)-induced diabetic arteriosclerosis. METHODS AND RESULTS As compared with LRP6(fl/fl);LDLR(-/-) controls, SM22-Cre;LRP6(fl/fl);LDLR(-/-) (LRP6-VKO) siblings exhibited increased aortic calcification on high-fat diet without changes in fasting glucose, lipids, or body composition. Pulse wave velocity (index of arterial stiffness) was also increased. Vascular calcification paralleled enhanced aortic osteochondrogenic programs and circulating osteopontin (OPN), a matricellular regulator of arteriosclerosis. Survey of ligands and Frizzled (Fzd) receptor profiles in LRP6-VKO revealed upregulation of canonical and noncanonical Wnts alongside Fzd10. Fzd10 stimulated noncanonical signaling and OPN promoter activity via an upstream stimulatory factor (USF)-activated cognate inhibited by LRP6. RNA interference revealed that USF1 but not USF2 supports OPN expression in LRP6-VKO vascular smooth muscle lineage, and immunoprecipitation confirmed increased USF1 association with OPN chromatin. ML141, an antagonist of cdc42/Rac1 noncanonical signaling, inhibited USF1 activation, osteochondrogenic programs, alkaline phosphatase, and vascular smooth muscle lineage calcification. Mass spectrometry identified LRP6 binding to protein arginine methyltransferase (PRMT)-1, and nuclear asymmetrical dimethylarginine modification was increased with LRP6-VKO. RNA interference demonstrated that PRMT1 inhibits OPN and TNAP, whereas PRMT4 supports expression. USF1 complexes containing the histone H3 asymmetrically dimethylated on Arg-17 signature of PRMT4 are increased with LRP6-VKO. Jmjd6, a demethylase downregulated with LRP6 deficiency, inhibits OPN and TNAP expression, USF1: histone H3 asymmetrically dimethylated on Arg-17 complex formation, and transactivation. CONCLUSIONS LRP6 restrains vascular smooth muscle lineage noncanonical signals that promote osteochondrogenic differentiation, mediated in part via USF1- and arginine methylation-dependent relays.
Collapse
Affiliation(s)
- Su-Li Cheng
- From the Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Cardiovascular Pathobiology, Orlando, FL (S.-L.C., B.R., A.B., M.M., C.S., Y.B.A., K.K., L.M.B., R.P., D.A.T.); MD Anderson Cancer Center, Cancer Biology, Houston, TX (J.-S.S.); Washington University, Department of Medicine, St. Louis, MO (K.K., A.K.); and Van Andel Research Institute, Department of Cancer and Cell Biology, Grand Rapids, MI (B.O.W.)
| | - Bindu Ramachandran
- From the Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Cardiovascular Pathobiology, Orlando, FL (S.-L.C., B.R., A.B., M.M., C.S., Y.B.A., K.K., L.M.B., R.P., D.A.T.); MD Anderson Cancer Center, Cancer Biology, Houston, TX (J.-S.S.); Washington University, Department of Medicine, St. Louis, MO (K.K., A.K.); and Van Andel Research Institute, Department of Cancer and Cell Biology, Grand Rapids, MI (B.O.W.)
| | - Abraham Behrmann
- From the Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Cardiovascular Pathobiology, Orlando, FL (S.-L.C., B.R., A.B., M.M., C.S., Y.B.A., K.K., L.M.B., R.P., D.A.T.); MD Anderson Cancer Center, Cancer Biology, Houston, TX (J.-S.S.); Washington University, Department of Medicine, St. Louis, MO (K.K., A.K.); and Van Andel Research Institute, Department of Cancer and Cell Biology, Grand Rapids, MI (B.O.W.)
| | - Jian-Su Shao
- From the Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Cardiovascular Pathobiology, Orlando, FL (S.-L.C., B.R., A.B., M.M., C.S., Y.B.A., K.K., L.M.B., R.P., D.A.T.); MD Anderson Cancer Center, Cancer Biology, Houston, TX (J.-S.S.); Washington University, Department of Medicine, St. Louis, MO (K.K., A.K.); and Van Andel Research Institute, Department of Cancer and Cell Biology, Grand Rapids, MI (B.O.W.)
| | - Megan Mead
- From the Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Cardiovascular Pathobiology, Orlando, FL (S.-L.C., B.R., A.B., M.M., C.S., Y.B.A., K.K., L.M.B., R.P., D.A.T.); MD Anderson Cancer Center, Cancer Biology, Houston, TX (J.-S.S.); Washington University, Department of Medicine, St. Louis, MO (K.K., A.K.); and Van Andel Research Institute, Department of Cancer and Cell Biology, Grand Rapids, MI (B.O.W.)
| | - Carolyn Smith
- From the Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Cardiovascular Pathobiology, Orlando, FL (S.-L.C., B.R., A.B., M.M., C.S., Y.B.A., K.K., L.M.B., R.P., D.A.T.); MD Anderson Cancer Center, Cancer Biology, Houston, TX (J.-S.S.); Washington University, Department of Medicine, St. Louis, MO (K.K., A.K.); and Van Andel Research Institute, Department of Cancer and Cell Biology, Grand Rapids, MI (B.O.W.)
| | - Karen Krchma
- From the Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Cardiovascular Pathobiology, Orlando, FL (S.-L.C., B.R., A.B., M.M., C.S., Y.B.A., K.K., L.M.B., R.P., D.A.T.); MD Anderson Cancer Center, Cancer Biology, Houston, TX (J.-S.S.); Washington University, Department of Medicine, St. Louis, MO (K.K., A.K.); and Van Andel Research Institute, Department of Cancer and Cell Biology, Grand Rapids, MI (B.O.W.)
| | - Yoanna Bello Arredondo
- From the Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Cardiovascular Pathobiology, Orlando, FL (S.-L.C., B.R., A.B., M.M., C.S., Y.B.A., K.K., L.M.B., R.P., D.A.T.); MD Anderson Cancer Center, Cancer Biology, Houston, TX (J.-S.S.); Washington University, Department of Medicine, St. Louis, MO (K.K., A.K.); and Van Andel Research Institute, Department of Cancer and Cell Biology, Grand Rapids, MI (B.O.W.)
| | - Attila Kovacs
- From the Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Cardiovascular Pathobiology, Orlando, FL (S.-L.C., B.R., A.B., M.M., C.S., Y.B.A., K.K., L.M.B., R.P., D.A.T.); MD Anderson Cancer Center, Cancer Biology, Houston, TX (J.-S.S.); Washington University, Department of Medicine, St. Louis, MO (K.K., A.K.); and Van Andel Research Institute, Department of Cancer and Cell Biology, Grand Rapids, MI (B.O.W.)
| | - Kapil Kapoor
- From the Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Cardiovascular Pathobiology, Orlando, FL (S.-L.C., B.R., A.B., M.M., C.S., Y.B.A., K.K., L.M.B., R.P., D.A.T.); MD Anderson Cancer Center, Cancer Biology, Houston, TX (J.-S.S.); Washington University, Department of Medicine, St. Louis, MO (K.K., A.K.); and Van Andel Research Institute, Department of Cancer and Cell Biology, Grand Rapids, MI (B.O.W.)
| | - Laurence M Brill
- From the Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Cardiovascular Pathobiology, Orlando, FL (S.-L.C., B.R., A.B., M.M., C.S., Y.B.A., K.K., L.M.B., R.P., D.A.T.); MD Anderson Cancer Center, Cancer Biology, Houston, TX (J.-S.S.); Washington University, Department of Medicine, St. Louis, MO (K.K., A.K.); and Van Andel Research Institute, Department of Cancer and Cell Biology, Grand Rapids, MI (B.O.W.)
| | - Ranjan Perera
- From the Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Cardiovascular Pathobiology, Orlando, FL (S.-L.C., B.R., A.B., M.M., C.S., Y.B.A., K.K., L.M.B., R.P., D.A.T.); MD Anderson Cancer Center, Cancer Biology, Houston, TX (J.-S.S.); Washington University, Department of Medicine, St. Louis, MO (K.K., A.K.); and Van Andel Research Institute, Department of Cancer and Cell Biology, Grand Rapids, MI (B.O.W.)
| | - Bart O Williams
- From the Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Cardiovascular Pathobiology, Orlando, FL (S.-L.C., B.R., A.B., M.M., C.S., Y.B.A., K.K., L.M.B., R.P., D.A.T.); MD Anderson Cancer Center, Cancer Biology, Houston, TX (J.-S.S.); Washington University, Department of Medicine, St. Louis, MO (K.K., A.K.); and Van Andel Research Institute, Department of Cancer and Cell Biology, Grand Rapids, MI (B.O.W.)
| | - Dwight A Towler
- From the Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Cardiovascular Pathobiology, Orlando, FL (S.-L.C., B.R., A.B., M.M., C.S., Y.B.A., K.K., L.M.B., R.P., D.A.T.); MD Anderson Cancer Center, Cancer Biology, Houston, TX (J.-S.S.); Washington University, Department of Medicine, St. Louis, MO (K.K., A.K.); and Van Andel Research Institute, Department of Cancer and Cell Biology, Grand Rapids, MI (B.O.W.).
| |
Collapse
|
53
|
Müller-Kuller U, Ackermann M, Kolodziej S, Brendel C, Fritsch J, Lachmann N, Kunkel H, Lausen J, Schambach A, Moritz T, Grez M. A minimal ubiquitous chromatin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic remodeling in multipotent and pluripotent stem cells. Nucleic Acids Res 2015; 43:1577-92. [PMID: 25605798 PMCID: PMC4330381 DOI: 10.1093/nar/gkv019] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Epigenetic silencing of transgene expression represents a major obstacle for the efficient genetic modification of multipotent and pluripotent stem cells. We and others have demonstrated that a 1.5 kb methylation-free CpG island from the human HNRPA2B1-CBX3 housekeeping genes (A2UCOE) effectively prevents transgene silencing and variegation in cell lines, multipotent and pluripotent stem cells, and their differentiated progeny. However, the bidirectional promoter activity of this element may disturb expression of neighboring genes. Furthermore, the epigenetic basis underlying the anti-silencing effect of the UCOE on juxtaposed promoters has been only partially explored. In this study we removed the HNRPA2B1 moiety from the A2UCOE and demonstrate efficient anti-silencing properties also for a minimal 0.7 kb element containing merely the CBX3 promoter. This DNA element largely prevents silencing of viral and tissue-specific promoters in multipotent and pluripotent stem cells. The protective activity of CBX3 was associated with reduced promoter CpG-methylation, decreased levels of repressive and increased levels of active histone marks. Moreover, the anti-silencing effect of CBX3 was locally restricted and when linked to tissue-specific promoters did not activate transcription in off target cells. Thus, CBX3 is a highly attractive element for sustained, tissue-specific and copy-number dependent transgene expression in vitro and in vivo.
Collapse
Affiliation(s)
- Uta Müller-Kuller
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Hessen, 60596, Germany
| | - Mania Ackermann
- RG Reprogramming and Gene Therapy, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany Institute of Experimental Hematology, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany
| | - Stephan Kolodziej
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Hessen, 60596, Germany
| | - Christian Brendel
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Hessen, 60596, Germany
| | - Jessica Fritsch
- RG Reprogramming and Gene Therapy, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany Institute of Experimental Hematology, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany
| | - Nico Lachmann
- RG Reprogramming and Gene Therapy, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany Institute of Experimental Hematology, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany
| | - Hana Kunkel
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Hessen, 60596, Germany
| | - Jörn Lausen
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Hessen, 60596, Germany
| | - Axel Schambach
- Institute of Experimental Hematology, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Thomas Moritz
- RG Reprogramming and Gene Therapy, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany Institute of Experimental Hematology, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany
| | - Manuel Grez
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Hessen, 60596, Germany
| |
Collapse
|